Montevideo Summer School

Health technology assessment research in Personalized Medicine

A total of 20 researchers from European and LAC countries —priority given to those from LAC countries— will participate in a Training event with the aim of improving and sharing the appropriate knowledge and skills that will allow them to improve understanding of the health technology assessment (HTA) processes to increase the research skills contributing to the HTA process.

The Summer School participation fee is free and open to 20 LAC & EU participants who will be evaluated and admitted on a competitive basis. Each eligible applicant will be evaluated according to three criteria: academic potential; experience in the Summer School topics; personal motivation (including the usefulness of this training in their current activity).

The EULAC-PerMed will award a scholarship to six participants. The successful candidates will receive non-cash support to cover accommodation costs and travel expense.

The documents to be submitted electronically (english) for this purpose are: the Curriculum Vitae; a clear reference to the candidate’s academic qualifications; the application form with the candidate’s interest in participating in the Summer School and a Reference letter.

Relevant documentation related to the workshop is now available below:


  • Program [PDF]
  • Application Process and Evaluation Criteria [PDF]
  • Application Form [Word]
  • Press Release [PDF]
  • Speakers presentations
Project Overview.
Health Technology Assessment Research & Personalized Medicine.
Health Technology Assessment Research and Precision Medicine.
Health Thechnology Assessment on clinical oncology Screening.
Health Technology Assessment on Clinical Oncology: Diagnosis and Treatment.
Red Nacional de Grupos Oncológicos (RedNaGO) – Uruguay.
ERAPerMed, Joint Transnational Call 2020.
Precision Medicine and Infectious Diseases.
Role of Health Technology Assessment in Rare Diseases: Perspectives of a clinician.
Clinical Trial Data Sharing: Role of infrastructure in EU and global efforts.
Clinical trials in Advanced Therapy Medicine Products.
Incorporating polygenic risk scores for common diseases from the ChileGenomico Project in population risk predictions by the Ministry of Health of Chile.
HTA: the experience of Uruguay.